>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: FNSR -22%, CPST -3.8%.

Select EU financial related names showing weakness: NBG -2.3%, LYG -1.3%, CS -1.1%, ING -1%, DB -0.8%, HSBC -0.6%, SAN -0.5%.

Other news: ETRM -7.3% (FDA releases update from review of EnteroMedics' VBLOC implantable medical device), AXAS -3.3% (announces an acceleration in 2014 Eagle Ford activity and provide the following guidance update; Co raises production guidance to 5,800-6,000 Boepd, up from 5,500-5,700), COMM -3.3% (upsizes its secondary offering by 2.5 mln shares and prices 17.5 mln shares of common stock at $23.00 per share), QCOR -2% (Mallinckrodt (MNK) shareholders must consider risks of QCOR deal, according to reports), NVO -1.8% (still checking), TTM -1.4% (weak India markets today), DLNG -1.2% (priced public offering of 4.8 mln common units at $22.79 per unit), MT -1.1% (still checking), APAM -0.8% (announced secondary offering of ~1.84 mln shares of common stock by selling shareholders).

Analyst comments: CCG -2.4% (downgraded to Underperform from Neutral at BofA/Merrill), BLL -0.7% (downgraded to Neutral from Buy at BofA/Merrill), MRVL -0.6% (downgraded to Neutral from Positive at Susquehanna).

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: INTC +6.9%.

M&A news: OPEN +13.1% prior to halt (will be acquired by Priceline (PCLN) for $103/share), CGG +7.8% (hearing BHI for CGG speculation as catalyst), PCLN +0.7% (acuiring OPEN for $103/share).

Select INTC peers/related names showing strength: AMD +2.3%, HPQ +1.7%, MSFT +1.3%, MSFT +1.3%, NVDA +0.9%.

Select OPEN peers trading higher: LIVE +14.7%, YELP +11.9%, GRPN +11.3%, GRUB +8.6%.

Select oil/gas related names showing strength: CEO +2.3%, SDRL +1.5%, RDS.A +1.1%, BP +1.1%, STO +0.9%, APA +0.9%, SNP +0.8%, TOT +0.5%.

Other news: ICLD +18.9% (announces it has become a VMware (VMW) partner and the opening of a New England Sales Office), NKTR +7.7% (Nektar Therapeutics confirms U.S. FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (pamora) class including movantik), ARO +4.8% (higher following Sycamore Partners expressing interest in acquire Express), NEPT +4.1% (Sherbrooke plant to resume production), FCSC +4% (receives orphan drug designation for genetically-modified autologous human fibroblasts to advance treatment development for recessive dystrophic epidermolysis bullosa), BOTA +3.6% (CEO & President Russel Plumb purchases approx 32K shares at an avg price of $2.99; EVP, Corporate Dev & Strategies Jopseph Patti purchases approx 14K shares- Form 4 Filings, YGE +3.3% (Malaysia's largest operational solar power plant powered by over 10 MWs of Yingli Solar modules), P +3% (still checking), CHSP +2.2% (to replace JOSB in the S&P SmallCap 600), BOBE +1.9% (featured on Mad Money), XEC +1.6% (to replace IGT in the S&P 500), LGND +1.3% (partner GSK announces results of Phase 3 PETIT2 study of Eltrombopag ), BTG +1.1% (announces Otjikoto Project Update; additional high grade drill results from the Wolfshag Zone).

Analyst comments: BRC +4.9% (upgraded to Buy from Underperform at BofA/Merrill), FIO +3.3% (initiated with a Buy at ROTH Capital), NMBL +3.3% (upgraded to Strong Buy at Raymond James), MNKD +2.2% (initiated with Outperform and $16 tgt at RBC Capital Mkts), PVA +2% (upgraded to Buy from Hold at Stifel), SRCL +1.9% (upgraded to Outperform at Robert W. Baird), CMCM+1.6% (initiated with Outperform at OPCO), EDR +1% (upgraded to Buy from Neutral at BofA/Merrill)

LEs Echos : CGG

CGG grimpe de plus de 8% dans volumes d’échanges importants. L’américain Baker Hugues pourrait faire une offre sur la parapétrolière française, indique Bloomberg.

CGG affiche de loin la plus forte hausse duSRD en début d’après-midi, le titre de la parapétrolière grimpant de plus de 8% à 10,65 euros, après un gain de plus de 12% au plus haut de la séance. Les volumes sont plus de deux fois supérieurs à la normale. Selon, Jawaid Asfar, trader britannique chez Securequity, dont les propos sont relayés par l’agence Bloomberg, l’américain Baker Hughes envisagerait une offre sur le français. Un porte-parole de CGG interrogé par Bloomberg n’a pas souhaité commenter cette rumeur.
Dans la matinée, une autre information était évoquée par la même agence. Selon le magazine Upstream, la filiale WesternGeco de Schlumberger et CGG seraient en lice pour un contrat de sismique d’au moins 100 millions de dollars auprès de l’indien ONGC. Ce dernier serait prêt à débourser un total de 1,1 milliard de dollars pour relancer le champ offshore de Mumbai High. Et selon Upstream, le français pourrait être préféré car il aurait présenté un prix inférieur à son concurrent.
Plus généralement, l’ensemble du secteur pétrolier et parapétrolier est soutenu par la hausse des cours du pétrole, sur fond de tensions géopolitiques en Irak.

>>> US Early premarket gappers

Early premarket gappers

Gapping up: NKTR +10.8%, INTC +5.3%, ARO +4.5%, NMBL +4.4%, BOTA +3.6%, ARRS +2.3%, CHSP +1.6%, SDRL +1.4%, HPQ +1.2%, NVDA +1.1%, XEC +0.9%, RDS.A +0.9%, BP +0.8%, STO +0.8%, SNP +0.8%, MSFT +0.7%

Gapping down: FNSR -21.5%, CPST -5.8%, NBG -3.7%, JDSU -2.6%, APAM -2.6%, AFOP -2.4%, QIHU -2%, TTM -1.6%, AXAS -1.4%, MT -1.4%, CIEN -1.3%, LYG -1.3%, SN -1.2%, CS -1.1%, DB -1.1%, COMM -1%, ING -1%, SAN -0.6%, HSBC -0.6%

>>> Allergan,Pershing Square Files Lawsuit in Delaware Court of Chancery Seeking


Allergan,Pershing Square Files Lawsuit in Delaware Court of Chancery Seeking Confirmation that Allergan’s Rights Plan Is Not Triggered by Efforts to Call a Special Meeting
- Announced today that an affiliate has filed a lawsuit in the Delaware Court of Chancery seeking a declaratory judgment confirming that its actions in connection with the solicitation and receipt of revocable proxies to call a special meeting of shareholders of Allergan, Inc. (Allergan) (NYSE:AGN) will not trigger Allergans recently adopted poison pill. 
- Allergans defensive reaction to the business combination transaction proposed by Valeant Pharmaceuticals International, Inc. (Valeant) (NYSE:VRX) has raised speculation that Allergan might try to assert that a shareholders compliance with the unprecedented procedures in Allergans bylaws somehow triggers the poison pill. Using a poison pill to silence shareholders or prevent them from exercising their voting rights is unlawful. In light of Allergans actions to date, and in order to remove any concern shareholders might have in participating in calling for a special meeting, Pershing Square had no alternative but to take this action. 
- The lawsuit followed a request by Pershing Square on June 6, 2014 to Allergan seeking confirmation that Allergan would not use its poison pill to frustrate its own bylaws and impede the calling of a special meeting. A response from Allergans counsel on June 11, 2014 failed to provide the confirmation requested. 
- The complaint can be found here: {http://www.vpsevent.com/chancerycomplaint-06-12-14.pdf}

(BFW) *UNITED INTERNET TO BUY BACK UP TO 2M SHRS THROUGH SEPT. 2017

BFW 06/13 09:46 *UNITED INTERNET TO BUY BACK UP TO 2M SHRS THROUGH SEPT. 2017
 BN 06/13 09:40 *UNITED INTERNET SAYS BUYBACK PERIOD RUNS UNTIL SEPT. 22, 2017
 BN 06/13 09:40 *UNITED INTERNET CURRENTLY HOLDS 557,077 TREASURY SHRS
 BN 06/13 09:39 *UNITED INTERNET TO BUY BACK UP TO 2M SHRS
 BN 06/13 09:39 *UNITED INTERNET DECIDES TO BUY BACK FURTHER TREASURY SHRS
 BN 06/13 09:39 * UNITED INTERNET DECIDES TO BUY BACK FURTHER TREASURY SHRS
DGAP-Adhoc: United Internet decides to buy back further treasury shares
2014-06-13 09:39:18.886 GMT


DGAP-Adhoc: United Internet decides to buy back further treasury shares

United Internet AG  / Key word(s): Share Buyback

13.06.2014 11:39

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.